GHIT invests in GeneDesign and DNDi partnership to develop a better treatment for cutaneous leishmaniasis

Cutaneous leishmaniasis patient in Colombia
Cutaneous leishmaniasis patient in Colombia

The Global Health Innovative Technology Fund (GHIT Fund) has announced today that it will invest in innovative malaria eradication tools, a new diagnostic test for tuberculosis, and new treatments for cutaneous leishmaniasis and soil-transmitted helminthiasis infections.

GHIT awarded US$687,715 to a partnership between GeneDesign, Inc., a Japan-based biotech, and DNDi to develop a better treatment for cutaneous leishmaniasis. With GHIT’s investment, GeneDesign and DNDi will assess an immunomodulator with an anti-parasitic drug to enhance healing and parasite clearance of skin lesions. This proposed approach shows potential to work faster than current drugs, reduce scarring, and prevent relapse.

Read the press release by the GHIT Fund

 

Photo credit: Fabio Nascimento-DNDi